Posted on 05/16/2006 7:21:19 PM PDT by neverdem
Scientists have identified a new molecule that inhibits proliferation of a broad range of lethal malignant glioma cells in vitro and in vivo. The findings, published in the May issue of Cancer Cell, shed light on which PI3 kinase family members are most likely to play a role in cancer progression. This study reinforces the concept that successful small molecule kinase inhibitors must display a broad reactivity to effectively attenuate the complex signaling pathways involved in malignant transformation and to thwart to the ability of cancer cells to adapt to stress.
Lipid kinases belonging to the PI3 kinase family, made up of different isoforms, promote cell growth and survival. Aberrant regulation and activation of PI3 kinases has been implicated in several human malignancies. Although the specific mechanisms and PI3K-associated molecules involved in cancer are not clear, this kinase family represents a rational and promising target for design of new cancer therapeutics. Dr. William A. Weiss, from the Department of Neurology at the University of California, San Francisco and coworkers sought to identify which PI3 kinase isoforms are critical for growth and progression of malignant glioma cells. UCSF colleagues Zachary Knight and Kevan Shokat synthesized and characterized a series of novel inhibitors that span the different PI3 kinase isoforms (described in the May issue of Cell). Qi-Wen Fan in the Weiss lab screened these agents in glioma cell lines. One compound, PI-103, uniquely and potently blocked the growth of glioma cells.
The cellular activity of PI-103 was traced to its ability to cooperatively inhibit both the p110á subunit of PI3 kinase and a downstream molecule called mTOR that also plays a critical role in cell growth. Although both of these molecules are members of the same signaling cascade, the researchers found that they must be concurrently inhibited because of a regulatory feedback loop that renders a monospecific inhibitor ineffective. Importantly, dual inhibition of p110á and mTOR with a low dose of PI-103 elicited no drug-related toxicity and was highly effective against human gliomas transplanted into mice.
"These data suggest that combinatorial inhibition of mTOR and p110á represents a safe and effective therapy in the treatment of cancers driven by aberrant signaling through PI3 kinase," says Dr. Weiss. "Glioma represents the most common primary brain tumor, and there are no curative medical therapies. Ultimately, we believe that PI-103 displays the hallmarks of the most successful cancer therapeutics that have been discovered to date as it exhibits a broad action without harmful side effects."
The researchers include Qi-Wen Fan, Zachary A. Knight, David D. Goldenberg, Wei Yu, Keith E. Mostov, David Stokoe, and William A. Weiss of the University of California, San Francisco in San Francisco, CA; Kevan M. Shokat of the Howard Hughes Medical Institute and the University of California, San Francisco in San Francisco, CA. This work was supported by the Brain Tumor Society, the Goldhirsh and Samuel G. Waxman Foundations, the Sandler Family, and the Brain Tumor SPORE Program.
Fan et al.: "A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma." Publishing in Cancer Cell 9, 341-349, May 2006. DOI 10.1016/j.ccr.2006.03.029 www.cancercell.org.
Wow!
I guess the next question is: are these isoforms, specifically PI-103 (or something equivalent) found in nature? If so, where? And are they in sufficient quantities to have an inhibitory effect?
That could be the next health food 'gold rush', or it might be as simple as eating your veggies like mom told you.
That is so damn cool!
bttt
Too bad you couldn't find the article in English. I believe this is about brain cancer isn't it?
Holy cow!
I have to assume PI3 kinase isoforms mean various versions of the enzyme PI3 kinase.
I guess the next question is: are these isoforms, specifically PI-103 (or something equivalent) found in nature? If so, where? And are they in sufficient quantities to have an inhibitory effect?
"One compound, PI-103, uniquely and potently blocked the growth of glioma cells."
I don't know if it's found in nature or not, but if, "PI-103, uniquely and potently blocked the growth of glioma cells," then it sounds like an effective inhibitor.
By determining how a class of compounds blocks signaling in cells, UCSF scientists have identified what is perhaps the most potent drug candidate yet against a highly lethal kind of brain tumor. The compound, known as PI-103, shows unique potency against cancer cell proliferation in studies of mice with grafts of human glioma cells. Gliomas are the most common form of brain cancer, and have proven very difficult to treat.The unique effectiveness of PI-103 stems from its ability to attack two separate steps in the series of signals that trigger the spread of cancer. The dual blockade proved to be a safe and effective inhibitor of cancer cell proliferation in mice with the human tumors, the scientists found.
The glioma research is being published online May 15 by the journal Cancer Cell. A description of the strategy used to identify the molecular level action of the inhibitors was published online by the journal Cell on April 27.
Food and Drug Administration approval five years ago of the cancer drug Gleevec marked a promising new strategy against cancer. Gleevec was the first drug on the market designed to block ubiquitous signaling molecules called protein kinases enzymes known to trigger normal cell proliferation, and in the case of cancer, the growth of tumors. Another group of kinases, called lipid kinases are now emerging as important new targets, especially PI3 alpha kinase, an enzyme often found to be overactive in brain, breast, colon and stomach cancers.
But the sheer number of related kinases 15 in the PI3 kinase family alone and uncertainty about how each acts in the body has stalled progress. Broad spectrum drugs that inhibit many related kinases inevitably cause toxicity and are poor drug candidates.
To overcome this hurdle, Kevan Shokat, PhD, a Howard Hughes Medical Institute investigator at UCSF, and Zachary Knight, a postdoctoral fellow in his lab, developed a strategy to systematically inhibit many different but related kinases to identify which ones might be prime targets to treat brain tumors. In the Cell paper they described their success synthesizing a panel of different PI3 kinase inhibitors, showing for the first time the structural basis of the inhibitors' abilities to block different PI3 kinases. They used the new compounds to dissect the role of PI3 kinases in insulin signaling and in cancer.
Drawing on this new tool, William Weiss, MD, associate professor of neurology at UCSF and an investigator in UCSF's Comprehensive Cancer Center, developed the strategy to treat gliomas. These cancers are the most common solid tumor of childhood, and about half of the people diagnosed with gliomas die within a year of diagnosis. Weiss and his colleagues report in the Cancer Cell paper that one PI3 kinase inhibitor in particular
PI-103 -- is unusually effective against gliomas in mice. They believe the inhibitor is a promising drug candidate, and a UCSF neuro-oncologist is developing plans to launch a clinical trial within a year, Weiss says.
The Weiss team discovered that the inhibitor's effectiveness lies in its dual impact. It inhibits both PI3 kinase and a protein kinase known as mTOR which acts "downstream" of PI3 kinase and is part of the cell's nutrient-sensing system. Clinical trials using inhibitors of mTOR alone have had disappointing results, Weiss says. One reason appears to be that the two kinases are part of a feedback loop. His group showed that mTOR inhibitors in clinical trials actually activate PI3-kinase while they inhibit mTOR. In effect, the drugs are blocking and encouraging cancer growth at the same time. The new inhibitor offers a mechanism through which to block both the PI3 and the mTOR kinase pathways, a strategy that appears to be particularly effective at slowing growth of gliomas.
Lead author on the Cancer Cell paper is Qi-Wen Fan, MD, PhD, assistant adjunct professor of neurology, in the Weiss lab. Co-authors along with Weiss, Shokat and Knight, all at UCSF, are David Goldenberg, staff research associate in neurology; Wei Yu, PhD, assistant research anatomist; and David Stokoe, PhD, assistant professor in the Cancer Research Institute.
Shokat, UCSF professor of cellular and molecular pharmacology, is also a faculty affiliate in QB3, the Institute for Quantitative Biomedical Research.
The bad news is: these molecules are only found in spotted owls and whales.
bttt
"Glioma represents the most common primary brain tumor, and there are no curative medical therapies."
I couldn't get that far. I'm only human. Please forgive me ;-)
Lactic Acid Is Not Muscles' Foe, It's Fuel
FReepmail me if you want on or off my health and science ping list.
More cellular and molecular biology results.
Within twenty years, they will be able to give a person a lifepan of two hundred years.
Whether they do or not, that will be a very interesting debate.
Thanks for the ping. I'm going to send this article along to a friend whose child has been fighting cancer for more years than not.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.